Login to Your Account

Pharma: Other news to note

Thursday, July 10, 2014
Baxter International Inc., of Deerfield, Ill., said it acquired Aesrx LLC, of Newton, Mass., gaining rights to Aes-103, developed in collaboration with researchers at the NIH's National Center for Advancing Translational Sciences, for treating the underlying mechanism of sickle cell disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription